ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Mass-Produced and High-Performance Nanowell Biosensor Fabricated via Semiconductor Manufacturing for Rapid and Accurate COVID-19 Diagnosis in the Clinical Field.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has underscored an urgent need for rapid, accurate, and accessible diagnostic tools to detect infections, facilitate timely quarantine, and inform therapeutic decisions. Fabricating nanostructures on biosensors can enhance biomolecule orientation, minimize steric hindrance, and reduce non-specific binding, resulting in improved signal-to-noise ratios and high sensitivity, making them promising point-of-care diagnostic. However, clinical translation remains limited by challenges in scalable and reproducible fabrication and insufficient diagnostic validation. Here, we introduce a nanowell biosensor (NW-Biosen) fabricated via semiconductor manufacturing, enabling scalable production and yields >1000 electrodes with reproducible properties. NW-Biosen detects SARS-CoV-2 antigens from patient nasal swabs within ∼10 min, with high sensitivity and minimal interference from other coronavirus recombinant proteins, respiratory pathogens, bacteria, and environmental substances, while maintaining consistent reproducibility with different batches. We validated NW-Biosen through two independent clinical trials involving 249 retrospective and 243 prospective patient samples. In prospective cohort, NW-Biosen achieved 93.02% sensitivity, 98.73% specificity, and a Cohen's kappa of 0.927, indicating near-perfect agreement with RT-PCR and superior sensitivity compared to commercially available colorimetric kits. Thus, NW-Biosen enables rapid, highly sensitive, reproducible, and cost-effective at-home detection, with real-time data transmission to public health authorities via mobile app integrated with a miniature potentiostat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.